It's Here! Adaptive MedEd! Join us to explore the latest clinical evidence for CAR T-cell therapy in relapsed/refractory CLL

Our dynamic learning experience is designed to enhance your ability to identify candidates for CAR T-cell therapy [PRIME]( [Accelerating the Adoption of CAR T-Cell Therapy Into Clinical Practice for CLL Treatment]( [Start Activity Now >>]( We are excited to invite you to the first part of our dynamic learning experience designed to enhance your ability to identify candidates for CAR T-cell therapy in chronic lymphocytic leukemia (CLL) and deepen your knowledge of the latest clinical evidence for CAR T-cell therapy in relapsed/refractory CLL. Prepare to elevate your expertise and transform your approach to CLL management to improve patient outcomes. In this session, you will: - Identify individuals with higher-risk CLL who could benefit from CAR T-cell therapy based on patient factors, disease characteristics, and line of therapy - Evaluate the latest clinical safety and efficacy data on emerging CAR T-cell therapies for the treatment of relapsed/refractory CLL Join us to gain valuable insights and advance your CLL management strategies. [0.5 CME/CE | AdaptiveMed]( [For More Information Click Here]( Expert Faculty: Danielle M. Brander, MD Contributing Author Assistant Professor of Medicine Division of Hematologic Malignancies & Cellular Therapy Duke University Medical Center Durham, NC Catherine C. Coombs, MD Contributing Author Associate Clinical Professor Division of Hematology/Oncology, Department of Medicine UCI Health Irvine, CA [Start Activity Now >>]( [Prime Education] PRIME Education, LLC 114 5th Ave, 14th Floor New York, NY 10011 (954) 718-6055 | [Contact us]( PRIME is a multi-disciplinary accredited provider of continuing medical education. [Unsubscribe from future emails](lst=NL_Prime_Specialty_Newsletters) | [Contact us]( | [COVID-19 Resource Center](